A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer (ARC-9)

The purpose of this study is to help understand whether an investigational drug, AB928 (referred to as etrumadenant and “etruma”), is safe and effective when given in combination with other therapies to patients with metastatic colorectal cancer (mCRC). Etruma may be combined with other investigational drugs, known as AB680 and zimberelimab (AB122), or may be combined with drugs that are approved by the United States Food and Drug Administration (U.S. FDA) and other government agencies to treat mCRC.

Are you Eligible? (Inclusion Criteria)

• Are you ≥ 18 years?
• Do you have metastatic colorectal adenocarcinoma?
• Is your life expectancy ≥3 months?
• Are you able to take oral medications?